17,390 Shares in Tocagen Inc (TOCA) Acquired by Gamble Jones Investment Counsel

Gamble Jones Investment Counsel bought a new stake in Tocagen Inc (NASDAQ:TOCA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 17,390 shares of the company’s stock, valued at approximately $178,000. Gamble Jones Investment Counsel owned 0.09% of Tocagen as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. New York State Common Retirement Fund acquired a new stake in shares of Tocagen in the second quarter valued at about $108,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Tocagen in the second quarter worth about $165,000. Dowling & Yahnke LLC purchased a new position in shares of Tocagen in the fourth quarter worth about $169,000. California State Teachers Retirement System purchased a new position in shares of Tocagen in the second quarter worth about $179,000. Finally, BBR Partners LLC purchased a new position in shares of Tocagen in the third quarter worth about $181,000. Institutional investors and hedge funds own 37.16% of the company’s stock.

Tocagen Inc (TOCA) opened at $12.38 on Thursday. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07. Tocagen Inc has a 52 week low of $8.60 and a 52 week high of $17.95.

Tocagen (NASDAQ:TOCA) last issued its earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. sell-side analysts forecast that Tocagen Inc will post -2.66 earnings per share for the current year.

Several research firms have recently weighed in on TOCA. ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. BidaskClub downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Zacks Investment Research raised shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $23.67.

TRADEMARK VIOLATION NOTICE: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2018/02/08/17390-shares-in-tocagen-inc-toca-acquired-by-gamble-jones-investment-counsel.html.

Tocagen Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).

Institutional Ownership by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply